

【公報種別】特許法第17条の2の規定による補正の掲載

【部門区分】第1部門第1区分

【発行日】平成17年7月28日(2005.7.28)

【公開番号】特開2003-199581(P2003-199581A)

【公開日】平成15年7月15日(2003.7.15)

【出願番号】特願2002-34378(P2002-34378)

【国際特許分類第7版】

C 1 2 N 15/09

C 1 2 N 5/10

C 1 2 Q 1/02

C 1 2 Q 1/68

G 0 1 N 33/15

G 0 1 N 33/50

G 0 1 N 33/53

G 0 1 N 33/566

【F I】

C 1 2 N 15/00 Z N A A

C 1 2 Q 1/02

C 1 2 Q 1/68 A

G 0 1 N 33/15 Z

G 0 1 N 33/50 Z

G 0 1 N 33/53 M

G 0 1 N 33/566

C 1 2 N 5/00 B

【手続補正書】

【提出日】平成16年10月15日(2004.10.15)

【手続補正1】

【補正対象書類名】明細書

【補正対象項目名】0040

【補正方法】変更

【補正の内容】

【0040】

【配列表】

SEQUENCE LISTING

<110> Japan Science And Technology Corporation
Sakamoto, Aiji

<120> A Method for Evalution or Identification for Bioactive Molecules
with the Use of Marker Genes.

<130> PC909155

<150> JP 2001-327576

<151> 2001-10-25

<160> 32

<170> PatentIn Ver. 2.1

<210> 1

<211> 900

<212> DNA

<213> Hamster sp.

<220>

<221> CDS

<222> (875)..(901)

<400> 1

```

tagcgctacc ggactcagat ctcgaggaag ctgtgtgacc ttggaggagg cactcccacc 60
tccataaact aaagcactca ctgggatgga tcaccagaga cctgtctggc tctgaggctc 120
ggtgacctca acacattgtc tgctggccca aggaaagcgg tgcctgagcc agagttccag 180
tgtctaaact ctggtcattc ttcttcctcc ttaactagga agctgcctcc tagctgctcc 240
aatccagctg ccataccagg gccatgcccg actctgccct gcccctcttt gctgtggtaa 300
ctaggcccct tcccacctca gtgagatgtg ggactcaggc cagtagagta gggaggattc 360
tggaacaga gccaggctag tgctgggggc caggactcca aggggcagca tgccagggca 420
gggcaggggct ctgtctgcct aaggatcatg tggtcgttgt cagcttactc tgcagtgagc 480
tgtggaatgt aagagatatt ttctgttcgc tttagaccac cccacccttt ggaactcaga 540
ccctgaacat gccatgccac aacaatgacg accacttcca attgtttcct ggctgggggg 600
ggaggggggag cactgtttgg acaaggggaag ggggggagtc gagggggaaa tgcttttagt 660
gacaacagcc ctttctaaat ctggctaggg actgggtgca ggtgggggtg ggggcacctt 720
ctgccccata tatacaaccc ctgaggccag gtctgactct gagcagtctc ctgctgtttc 780
cttccttgct gccctcaggt aggagtggga gctggaggcc tcctctggga taaggggctc 840
cagattcagg aagagggatc caccggtcgc cacc atg gtg agc aag ggc gag gag 895
Met Val Ser Lys Gly Glu Glu

```

1

5

ctg ttc

901

Leu Phe

<210> 2

<211> 9

<212> PRT

<213> Hamster sp.

<400> 2

Met Val Ser Lys Gly Glu Glu Leu Phe

1

5

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

prepro-endothelin-1 (ppET-1) , forward primer

<400> 3

ccaaggagct ccagaaacag

20

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

prepro-endothelin-1(ppET-1) , reverse primer

<400> 4

ttgacccaga tgatgtccag

20

<210> 5

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

ETA endothelin receptor (ETAR) , forward primer

<400> 5

tctgcgcgct aagtgttgac aggt

24

<210> 6

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

ETA endothelin receptor (ETAR) , reverse primer

<400> 6

tcatcaggct ttaggactgg taac

24

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

ETB endothelin receptor (ETBR) , forward primer

<400> 7

tctctgtggt tctggctgtc

20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

ETB endothelin receptor (ETBR) , reverse primer

<400> 8

tgctgaggtg aaggggaagc

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

AT1 angiotensin receptor (AT1R) , forward primer

<400> 9

gctgaagact gtggccagt

20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
AT1 angiotensin receptor (AT1R) , reverse primer

<400> 10
atgcaggatga ctttggctac 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
1C adrenergic receptor (1cAR) , forward primer

<400> 11
tccacggatgc tgcccttctc 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
1C adrenergic receptor (1cAR) , reverse primer

<400> 12
ttgatctggc agatggtctc 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
gp130 (cardiotrophin-1 receptor) , forward primer

<400> 13

cagaatgtgt atggagtcac 20

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

gp130 (cardiotrophin-1 receptor) , reverse primer

<400> 14

accagactt caatgttgac 20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

transforming growth factor (TGF) , forward primer

<400> 15

aactattgct tcagctccac 20

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

transforming growth factor (TGF) , reverse primer

<400> 16

acgtagtaca cgatgggcag 20

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

protein kinase C (PKC) , forward primer

<400> 17
gcagccactg caccgacttc 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
protein kinase C (PKC) , reverse primer

<400> 18
acgtagggat ctgacaagcc 20

<210> 19
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
c-myc , forward primer

<400> 19
acagcaaacc tccgcacag 19

<210> 20
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
c-myc , reverse primer

<400> 20
tggtcacgca gggcaaaaa 19

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
c-fos , forward primer

<400> 21
gccccatcgc agaccagagc 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
c-fos , reverse primer

<400> 22
atgctgctga tgctcttgac 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
c-ras , forward primer

<400> 23
caccatagag gtgagctctg 20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
c-ras , reverse primer

<400> 24
tcctcttggc ctgctgtgtc 20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

-MHC , forward primer

<400> 25

cgcatggacc tggagcgagc

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

-MHC , reverse primer

<400> 26

cgccgcatct tccggaactc

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

GAPDH , forward primer

<400> 27

accacagtcc atgcatcac

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

GAPDH , reverse primer

<400> 28

tccaccaccc tgttgctgta

20

<210> 29

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
forward primer (F1)

<400> 29

cgctcgagga agctgtgtga ccttgag

28

<210> 30

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
reverse primer (R2)

<400> 30

cgggatccct cttcctgaat ctggagcc

28

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:GFP-F

<400> 31

tcgccaccat ggtgagcaag

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:GFP-R

<400> 32

cctagcagaa gcacaggctg

20